0.66
+0.0263(+4.18%)
Currency In USD
| Previous Close | 0.63 |
| Open | 0.63 |
| Day High | 0.66 |
| Day Low | 0.63 |
| 52-Week High | 5.85 |
| 52-Week Low | 0.4 |
| Volume | 580,909 |
| Average Volume | 1.8M |
| Market Cap | 52.55M |
| PE | 1.73 |
| EPS | 0.38 |
| Moving Average 50 Days | 0.66 |
| Moving Average 200 Days | 1.01 |
| Change | 0.03 |
If you invested $1000 in CytomX Therapeutics, Inc. (CTMX) since IPO date, it would be worth $50.85 as of April 20, 2025 at a share price of $0.656. Whereas If you bought $1000 worth of CytomX Therapeutics, Inc. (CTMX) shares 5 years ago, it would be worth $68.19 as of April 20, 2025 at a share price of $0.656.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
CytomX Therapeutics to Present at the Barclays 27th Annual Global Healthcare Conference
GlobeNewswire Inc.
Mar 05, 2025 1:00 PM GMT
SOUTH SAN FRANCISCO, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and c
CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
GlobeNewswire Inc.
Feb 27, 2025 1:00 PM GMT
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that it will report full year 2024 financial re
CytomX Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 08, 2025 1:00 PM GMT
SOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and ch
Data not available